Skip to content
HowShorted

Humacyte, Inc. short interest in 2023

In 2023, Humacyte, Inc.'s disclosed short interest ran from 4.23% of shares outstanding on 13 Jan 2023 to 5.83% on 29 Dec 2023, a change of +1.60 percentage points. The year's high was 5.88% on 15 Nov 2023 and its low 2.83% on 30 Jun 2023, averaging 4.55% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 45.66 days on 28 Apr 2023. Full history: Humacyte, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Humacyte, Inc. in 2023

2023 in figures

Start of year
4.23% (13 Jan 2023)
End of year
5.83% (29 Dec 2023)
Change
+1.60 pp
High
5.88% (15 Nov 2023)
Low
2.83% (30 Jun 2023)
Average
4.55%
Highest days to cover
45.66 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

Humacyte, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.23%17.90
31 Jan 20234.35%23.62
15 Feb 20234.66%21.36
28 Feb 20234.83%13.14
15 Mar 20234.93%19.91
31 Mar 20235.09%25.0710-K filed, results (8-K)
14 Apr 20235.04%34.91
28 Apr 20235.05%45.66
15 May 20235.35%12.8810-Q filed, results (8-K)
31 May 20234.18%11.61
15 Jun 20232.89%5.13
30 Jun 20232.83%3.90
14 Jul 20232.90%6.64
31 Jul 20232.91%8.57
15 Aug 20233.08%5.0510-Q filed, results (8-K)
31 Aug 20233.68%3.81
15 Sep 20235.08%5.19
29 Sep 20235.16%10.06
13 Oct 20234.93%14.81
31 Oct 20235.31%11.56
15 Nov 20235.88%8.3710-Q filed, results (8-K)
30 Nov 20235.66%20.79
15 Dec 20235.37%11.87
29 Dec 20235.83%16.98

See also: Humacyte, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.